Article Under Review
This article is undergoing editorial and medical review. We regularly update content as part of our commitment to providing patient-centered, accurate, evidence-based information.
Overview
You might wonder: What if something happens years after donation? What if I get cancer? Research on thousands of donors followed for 10, 20, or more years gives reassuring answers. Serious complications are extraordinarily rare.
Large studies show that donors do not have more cancer, heart disease, or other serious illness than the general public. Your bones stay strong. Your fertility is not affected. You can age the same way as anyone else. If you develop a health problem years after donation, it is probably unrelated to giving cells. Your coordination center tracks these rare events anyway, so you can report them and help the research.
Long-term safety of donation
Extensive research, particularly from the NMDP and CIBMTR, has followed thousands of donors for 10-20+ years. These studies examine cancer incidence, cardiovascular disease, infections, bone density, reproductive outcomes, and mortality. Across all outcomes studied, donors show no increased risk compared to the general population.
Safety research characteristics:
- Large diverse donor populations followed decades
- Examination of multiple health outcomes
- No increased risk across all measures studied
- Complications occur at expected population rates
- Donation safety confirmed long-term
This doesn't mean zero complications occur—rarely, donors develop complications years after donation. But these complications occur at expected rates in the general population and aren't attributable to donation itself. The transplant field is confident that donation is safe long-term.
What the research shows
PBSC donation
PBSC donors have no increased cancer risk. Studies show cancer incidence in PBSC donors is the same as in the general population. This is reassuring because one early concern was whether filgrastim (the growth factor used for mobilization) might increase leukemia risk. Research has definitively ruled this out.
Long-term PBSC donor outcomes:
- No increased cancer risk compared to general population
- Normal cardiovascular outcomes and cardiac events
- Lipid levels temporarily increase but normalize after mobilization
- Normal fertility and pregnancy outcomes
- No adverse effects on eggs or sperm from filgrastim
Bone health in PBSC donors is maintained. Bone density in PBSC donors is normal years after donation. No increased fracture risk occurs. Osteoporosis rates are no higher than expected.
Bone marrow donation
Bone marrow donors show similarly reassuring long-term outcomes. Cancer incidence is normal. Cardiovascular outcomes are normal. Bone density is maintained (the recovered marrow regenerates completely, and bone strength is unaffected). Fertility and pregnancy outcomes are normal.
Bone marrow donor long-term outcomes:
- Cancer incidence is normal
- Cardiovascular outcomes are normal
- Bone density maintained and strength unaffected
- Fertility and pregnancy outcomes are normal
- Chronic pain occurs in <5% of donors
Chronic pain after bone marrow donation occurs in fewer than 5% of donors and usually resolves within months to a year. Chronic pain persisting beyond 12 months is rare. Most long-term pain is mild and manageable.
Psychological well-being in donors:
- Most donors report satisfaction with decision
- Donors don't regret donation
- Some experience complicated emotions about outcomes
- Serious psychological harm is uncommon
- Support available through donor centers
Monitoring your health
While serious long-term complications from donation are rare, you should monitor your health with the same diligence as anyone. Get age-appropriate cancer screenings (mammograms, colonoscopies, skin checks). Monitor cardiovascular health (blood pressure, cholesterol, exercise). Be aware of new symptoms and report them to your doctor.
Health monitoring practices:
- Get routine cancer screenings
- Monitor cardiovascular health
- Report new diagnoses to your coordinator
- Health anxiety is normal but usually unwarranted
- Counseling helps if anxiety is significant
If you develop a new medical condition years after donation, report it to your coordination center. Most likely, it's unrelated to donation. The transplant system tracks these events to continuously monitor donor safety.
Managing health post-donation:
- Report new diagnoses to your coordination center
- Health anxiety is normal after donation
- Distinguish donation monitoring from general health monitoring
- Counseling available to address health anxiety
- Appropriate monitoring shows commitment to health
Rare complications
Rare long-term complications that have been reported in the literature include:
- Splenic rupture. Rare emergency during filgrastim mobilization (<1%) or months after. Symptoms: severe left upper abdominal pain, shortness of breath, lightheadedness. Seek emergency care immediately.
- Thromboembolic disease. Blood clots in veins or lungs are rare (<1%) after PBSC donation. Risk factors include immobility, cancer history, or clotting tendencies. Seek care if you develop calf pain/swelling or chest pain.
- Alloimmunization. Extremely rare antibody development to recipient's HLA or blood group antigens. Doesn't affect donor health but is tracked in research.
- Acute leukemia. Extraordinarily rare in filgrastim-mobilized donors. Large studies find no increased incidence.
When to see a doctor
Seek medical care for new symptoms years after donation if you develop: sudden severe abdominal pain (especially left upper abdomen, concerning for splenic issues), leg pain or swelling (blood clot concern), chest pain or shortness of breath, severe infections, or cancer diagnosis.
These symptoms are important whether or not you're a donor. If you develop them, see a doctor. After evaluating you, let your coordination center know about serious diagnoses—not because donation is necessarily related, but so your outcome data is complete.
Don't obsess over every ache and pain or worry that minor symptoms mean donation caused damage. Most symptoms are coincidental and unrelated to donation. Your health is probably fine. If something genuinely concerns you, see your doctor. That's appropriate health monitoring, not paranoia.
- Seek care for serious new symptoms
- Don't assume donation caused every symptom
- Report serious diagnoses to your coordinator
- Health anxiety is normal but usually unfounded
- Appropriate medical care when needed
Additional Detailed Information
Additional Information
Splenic rupture pathophysiology
Mobilization-related splenic rupture. During filgrastim mobilization, the spleen enlarges due to increased hematopoiesis and can rupture, particularly with trauma or strenuous activity. Risk increases with significant splenic enlargement (>15 cm). Screening ultrasound identifies high-risk donors; these donors are counseled to avoid strenuous activity during mobilization. Spontaneous rupture is rare; most ruptures follow trauma.
Delayed splenic rupture. Extremely rare reports exist of splenic rupture weeks to months after PBSC donation. The mechanism is unclear—possibly delayed splenic rebound hyperplasia or persistent changes. This complication is so rare that it's not considered a major concern affecting donation decisions.
Thromboembolic disease risk
Risk factors. Filgrastim mobilization increases thrombotic risk, particularly in donors with additional risk factors: malignancy history, thrombophilia, immobility, recent surgery, or use of estrogen-containing contraceptives. Most thromboembolic events in PBSC donors occur during mobilization, not afterward.
Prevention. Donors at high thrombotic risk might receive thromboprophylaxis (blood thinners). Low-molecular-weight heparin (enoxaparin) is sometimes used for high-risk donors. Mobilization duration should be minimized in high-risk donors.
Cancer surveillance and incidence data
Comparison with general population. Large cohort studies of PBSC donors (5,000+ donors followed 10-20 years) show cancer incidence not different from age-matched controls. Breast cancer, lung cancer, hematologic malignancies, and solid tumors all occur at expected rates.
Filgrastim and leukemia. Acute leukemia risk with filgrastim is not increased in donors. However, patients with certain conditions (particularly myelodysplastic syndrome) treated with filgrastim have increased leukemia transformation risk. This patient-specific risk doesn't translate to donors because donors are healthy.
Reproductive outcomes research
Fertility and conception. Studies of women donors show normal time to conception, normal pregnancy rates, and normal spontaneous abortion rates compared to control populations. Men donors show normal sperm parameters. Filgrastim exposure doesn't affect fertility.
Pregnancy and birth outcomes. Children born to donor mothers show normal birth weights, normal gestational ages, and normal congenital anomaly rates. No increase in pregnancy complications (gestational diabetes, preeclampsia, etc.) is observed. Filgrastim exposure in utero doesn't increase risk of congenital anomalies in studies examining this question.
Bone health and density
Bone density after PBSC. Donor spine and hip bone density measured years after PBSC donation is normal. PBSC donation doesn't increase fracture risk or osteoporosis risk. Filgrastim effects on bone are temporary and reversible.
Marrow regeneration after aspiration. Recovered bone marrow regenerates completely within 2-6 weeks. Long-term bone marrow cellularity is normal. No chronic myelosuppression or bone defects result from bone marrow aspiration.
Written By:
Transplants.org Staff
Last Reviewed: February 26, 2026
Informed By:
Transplants.org, with participation from 23 leading U.S. transplant centers, led the largest comparative analysis of patient educational materials in transplant history. We recognize the participating centers who helped inform and inspire our direction with initial patient-centered educational content:
- Mayo Clinic (Co-Author)
- Vanderbilt University Medical Center (Co-Author)
- Johns Hopkins Hospital (Co-Author)
- UCLA Medical Center (Co-Author)
- UCSF Medical Center (Co-Author)
Transplants.org is an independent nonprofit organization and participation is not an endorsement by these organizations.
